Editor’s note: A recording of this virtual event is embedded above. A version of this recording with closed captioning can be found on our YouTube page here.
Scientists are developing improved forms of genome editing, increasing the number of inherited diseases the technology may one day treat. Research veterans have a warning: be prepared for surprises. Join STAT as we speak with a panel of experts to share theories on how versatile CRISPR technologies may move from the lab to clinical trials.
Sponsor Introduction: Robert Deans, Ph.D., chief scientific officer, Synthego
- David R. Liu, Richard Merkin Professor and vice-chair of the faculty, Broad Institute; investigator, Howard Hughes Medical Institute; Thomas Dudley Cabot Professor of the Natural Sciences and professor of chemistry and chemical biology, Harvard University
- Alexis A. Thomspon, M.D., M.P.H., Sarah and A. Watson Armour Chair in childhood cancer and blood disorders, hematology section head, Ann & Robert H. Lurie Children’s Hospital of Chicago; professor of pediatrics, Feinberg School of Medicine, Northwestern University
- Gideon Gil, managing editor, STAT (moderator)